What it is
NAD+ is a coenzyme involved in redox reactions, energy metabolism, and DNA repair signaling. IV use belongs in a medical setting. Subcutaneous use remains investigational.
Evidence boundary
Limited and heterogeneous human evidence.
Trial evidence
- PMID 42514320 — Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.
- PMID 42289992 — The protective role of SIRT1 in cardiovascular disease: from molecular mechanisms to potential therapeutic strategies.
- PMID 42234350 — Targeted Supplementation and Nutritional Strategies for Healthy Aging: A Review of Physiological and Molecular Benefits.
- PMID 42628241 — Dynamics of blood NAD and glutathione in health, disease, aging, and under NAD(+)-booster treatment.
- PMID 42744962 — Association between whole-blood NAD+ concentration and frailty in community-dwelling older adults: the Itabashi Longitudinal Study.
Preparation and measurement
Reconstitution: 500 mg vial + 5 mL BAC = 100 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Tolerance phase | 20 mg | 20 U (0.2 mL) | 3 times/week | 60 mg/week |
| Standard research range | 20–50 mg | 20–50 U (0.2–0.5 mL) | 3–5 times/week | 60–250 mg/week |
| Week 1 (intensive-course source variant) | 50 mg | 50 U (0.5 mL) | Once daily | 350 mg/week |
| Week 2 (intensive-course source variant) | 75 mg | 75 U (0.75 mL) | Once daily | 525 mg/week |
| Week 3+ (intensive-course source variant) | 100 mg | 100 U (1 mL) | Once daily | 700 mg/week |
Tolerance phase
- Dose
- 20 mg
- Draw / measure
- 20 U (0.2 mL)
- Frequency
- 3 times/week
- Weekly total
- 60 mg/week
Standard research range
- Dose
- 20–50 mg
- Draw / measure
- 20–50 U (0.2–0.5 mL)
- Frequency
- 3–5 times/week
- Weekly total
- 60–250 mg/week
Week 1 (intensive-course source variant)
- Dose
- 50 mg
- Draw / measure
- 50 U (0.5 mL)
- Frequency
- Once daily
- Weekly total
- 350 mg/week
Week 2 (intensive-course source variant)
- Dose
- 75 mg
- Draw / measure
- 75 U (0.75 mL)
- Frequency
- Once daily
- Weekly total
- 525 mg/week
Week 3+ (intensive-course source variant)
- Dose
- 100 mg
- Draw / measure
- 100 U (1 mL)
- Frequency
- Once daily
- Weekly total
- 700 mg/week
Weekly totals apply only during the active phase.
Titration rules
-
The lower-dose protocol and the intensive daily protocol are separate reported schedules; do not combine them.
-
For the lower-dose protocol, the collected reference range is 20–50 mg per administration. Frequency is limited by injection-site tolerance.
-
The intensive source protocol moves 50 → 75 → 100 mg/day at one-week intervals. Do not compress those intervals.
-
Injection-site burning or discomfort
-
Flushing or warmth during or after dosing
-
Nausea or headache
Practical rules
- Keep IV use in a clinic.
- Keep the route explicit.
- Do not treat SQ dosing as a finished standard.
- Split large doses if sting is a problem.
Research coverage
Related reporting from Compound Chronicle, which tracks the peer-reviewed literature on NAD+.
- NAD+ and Frailty in Older Adults: New Human Evidence Sep 20, 2026
In 529 older adults, lower blood NAD+ was associated with frailty — human observational data from the Itabashi Longitudinal Study on Aging.
- NAD+ Research Is Widening — and So Are the Questions Aug 17, 2026
A batch of new NAD+ papers spans redox biology, cancer metabolism, and sirtuin signaling. The breadth is a reminder that NAD+ is a fundamental biochemistry topic, not just a supplement.